Alto Neuroscience, Inc. (ANRO) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 16.65M USD | Liabilities, Current |
| Cash and equivalents | 243.73M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $16.65M | $243.73M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $13.12M | $263.76M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $11.32M | $176.48M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $9.04M | $137.82M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $8.13M | $147.59M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $7.26M | $160.75M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $10.01M | $168.23M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.02M | $181.70M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $9.84M | $193.12M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $8.01M | $205.90M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $5.61M | $82.55M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |